<DOC>
	<DOCNO>NCT01894295</DOCNO>
	<brief_summary>The aim double blind clinical trial study investigate whether alphacalcidol treatment obese subject affect rest metabolic rate . Moreover , investigator evaluate pathway Nesfatin-1 , Peroxisome proliferator-activated receptor gamma ( PPARγ ) eroxisome proliferator-activated receptor- coactivator-1 α ( PGC1α ) protein may lead change metabic rate follow treatment either alphacalcidol placebo .</brief_summary>
	<brief_title>Assessment Vitamin D Analogues Intake Pathways Proteins Which Involved Metabolic Rate Obese Subjects</brief_title>
	<detailed_description />
	<mesh_term>Vitamins</mesh_term>
	<mesh_term>Vitamin D</mesh_term>
	<mesh_term>Ergocalciferols</mesh_term>
	<mesh_term>Hydroxycholecalciferols</mesh_term>
	<criteria>Age 2252 year Body mass index equal 30 Acute chronic inflammatory disease History hypertension Alcohol drug abuse History condition affect inflammatory marker Thyroid disease Malignancies Current smoking Diabetes mellitus Sustained hypertension Heart failure Acute chronic infection Hepatic renal disease Use PPARγ agonist drug</criteria>
	<gender>All</gender>
	<minimum_age>22 Years</minimum_age>
	<maximum_age>52 Years</maximum_age>
	<verification_date>July 2013</verification_date>
	<keyword>Vitamin D analogue</keyword>
	<keyword>Resting Metabolic rate</keyword>
	<keyword>obesity</keyword>
</DOC>